Purification of clinical-grade disulfide stabilized antibody fragment variable - Pseudomonas exotoxin conjugate (dsFv-PE38) expressed in Escherichia coli

Applied Microbiology and Biotechnology

Volumn 97, Issue 2, 2013, Pages 621-632

  Jiang, Hua ^a,c   Xie, Yueqing ^a   Burnette, Andrew ^a,d   Roach, John ^a   Giardina, Steven L ^a   Hecht, Toby T ^b,e   Creekmore, Stephen P ^b   Mitra, Gautam ^a   Zhu, Jianwei ^a  

^a SAIC FREDERICK INC   (United States)

^b FREDERICK NATIONAL LABORATORY FOR CANCER RESEARCH   (United States)

^c NOVAVAX INC   (United States)

^d Zyngenia Inc   (United States)

^e NATIONAL CANCER INSTITUTE   (United States)

Author keywords

cGMP production; Expression and purification; Immunotoxin; Refolding

Indexed keywords

AMMONIUM SULFATE PRECIPITATION; ANTIBODY FRAGMENT; CANCER-TARGETING; CELL LYSIS; CLINICAL MANUFACTURING; CLINICAL TRIAL; HYDROPHOBIC INTERACTIONS; IMMUNOTOXINS; INCLUSION BODIES; ION-EXCHANGE CHROMATOGRAPHY; MODEL PROTEINS; PRODUCTION OF; PRODUCTION PROCESS; PURIFICATION METHOD; REFOLDING; THIRD GENERATION;

ANTIBODIES; BACTERIA; ESCHERICHIA COLI; RECOVERY; TOXIC MATERIALS;

PURIFICATION;

AMMONIUM SULFATE; CD22 ANTIGEN; CYCLIC GMP; DISULFIDE STABILIZED ANTIBODY FV PORTION TOXIN CONJUGATE; EXOTOXIN; IMMUNOTOXIN; UNCLASSIFIED DRUG;

AMMONIUM SULFATE; ANTIBODY; COLIFORM BACTERIUM; HOMOGENEITY; ION CHROMATOGRAPHY; ION EXCHANGE; PROTEIN; TOXIN;

ANION EXCHANGE CHROMATOGRAPHY; ARTICLE; BIOMASS; CELL GROWTH; CELL INCLUSION; CYTOLYSIS; ESCHERICHIA COLI; GEL PERMEATION CHROMATOGRAPHY; GENETIC ENGINEERING; IMMUNOGENICITY; IN VIVO STUDY; ION EXCHANGE CHROMATOGRAPHY; NONHUMAN; PROTEIN FOLDING; PROTEIN PROTEIN INTERACTION; PROTEIN PURIFICATION; PROTEIN TARGETING; PSEUDOMONAS AERUGINOSA; SOLUBILIZATION;

ANTIBODIES; CYCLIC GMP; DISULFIDES; ESCHERICHIA COLI; EXOTOXINS; PSEUDOMONAS;

ANIMALIA; ESCHERICHIA COLI; PSEUDOMONAS EXOTOXIN;

EID: 84873994543     PISSN: 01757598     EISSN: 14320614     Source Type: Journal    
DOI: 10.1007/s00253-012-4319-2     Document Type: Article

References (49)

1. Archer GE, Sampson JH, Lorimer IAJ, McLendon RE, Kuan CT, Friedman AH, Friedman HS, Pastan IH, Bigner DD (1999) Regional treatment of epidermal growth factor receptor vIII-expressing neoplastic meningitis with a single-chain immunotoxin, MR-1. Clin Cancer Res 5:2646-2652
2. Bang S, Nagata S, Onda M, Kreitman RJ, Pastan I (2005) HA22 (R490A) is a recombinant immunotoxin with increased antitumor activity without an increase in animal toxicity. Clin Cancer Res 11:1545-1550
3. Batra JK, FitzGerald D, Gately M, Chaudhary VK, Pastan I (1990) Anti-Tac(Fv)-PE40, a single chain antibody Pseudomonas fusion protein directed at interleukin 2 receptor bearing cells. J Biol Chem 265:15198-15202
4. Beers R, Chowdhury C, Bigner D, Pastan I (2000) Immunotoxin with increased activity against epidermal growth factor receptor vIII-expressing cells produced by antibody phage display. Clin Cancer Res 6:2835-2843
5. Bird RE, Walker BW (1991) Single chain antibody variable regions. Trends Biotechnol 9:132-137
6. Bird RE, Hardman KD, Jacobson JW, Johnson S, Kaufman BM, Lee SM, Lee T, Pope SH, Riordan GS, Withlow M (1988) Single-chain antigen binding proteins. Science 242:423-426
7. Bjorn MJ, Groetsema G, Scalapino L (1986) Antibody - Pseudomonas exotoxin A conjugates cytotoxic to human breast cancer cells in vitro. Cancer Res 46:3262-3267
8. Brinkmann U, Pai LH, FitzGerald DJ, Willingham M, Pastan I (1991) B3(Fv)-PE38KDEL, a single-chain immunotoxin that causes complete regression of a human carcinoma in mice. Proc Natl Acad Sci U S A 88:8616-8620
9. Buchner J, Pastan I, Brinkmann U (1992) A method for increasing the yield of properly folded recombinant fusion proteins: single-chain immunotoxins from renaturation of bacterial inclusion bodies. Analyt Biochem 205:263-270
10. Chaudhary VK, Queen C, Junghans RP, Waldmann TA, FitzGerald DJ, Pastan I (1989) A recombinant immunotoxin consisting of two antibody variable domains fused to Pseudomonas exotoxin. Nature 339:394-397
11. FitzGerald DJ, Willingham MC, Pastan I (1988) Pseudomonas exotoxin - immunotoxins. Cancer Treatment Res 37:161-173
12. FitzGerald DJ, Wayne AS, Kreitman RJ, Pastan I (2011) Treatment of hematologic malignancies with immunotoxins and antibody-drug conjugates. Cancer Res 71:6300-6309
13. Frankel AE (2002) Increased sophistication of immunotoxins. Clin Cancer Res 8:942-944
14. Frankel AE, Kreitman RJ, Sausville EA (2000) Targeted toxins. Clin Cancer Res 6:326-334
15. Harmsen MM, De Haard HJ (2007) Properties, production, and applications of camelid single-domain antibody fragments. Appl Microbiol Biotechnol 77:13-22
16. Humphrey PA, Wong AJ, Vogelstein B, Friedman HS, Werner MH, Bigner DD, Bigner SH (1988) Amplification and expression of the epidermal growth factor receptor gene in human glioma xenografts. Cancer Res 48:2231-2238
17. Huston JS, Levinson D, Mudgett-Hunter M, Tai MS, Novotny J, Margolies MN, Ridge RJ, Bruccoleri EH, Crea R, Oppermann H (1988) Protein engineering of antibody binding sites: recovery of specific activity in an anti-dogoxigenin single-chain Fv analogue produced in Escherichia coli. Proc Nat Acad Sci (Wash) 85:5879-5883
18. Iglewski BH, Kabat D (1975) NAD-dependent inhibition of protein synthesis by Pseudomonas aeruginosa toxin. Proc Nat Acad Sci U S A 72:2284-2288
19. Kreitman RJ (2006) Immunotoxins for targeted cancer therapy. The AAPS Journal 8 (3) Article 63:E532-E551. doi: 10.1208/aapsj080363
20. Kreitman RJ (2009) Recombinant immunotoxins for the treatment of chemoresistant hematologic malignancies. Cur Pharm Des 15:2652-2664
21. Kreitman RJ (2012) A phase 1/II study of CAT-8015 in adult relapsed or refractory B-cell non Hodgkin lymphoma and chronic lymphocytic leukemia. NCI-10-C-0067, NCT01086644. http://bethesdatrials.cancer.gov/clinical-research/ search-detail.aspx?ProtocolID=NCI-10-C-0067 (2012) retrieved May 17, 2012
22. Kreitman RJ, Wang QC, FitzGerald DP, Pastan I (1999) Complete regression of human B-cell lymphoma xenografts in mice treated with recombinant anti-CD22 immunotoxin RFB4(dsFv)-PE38 at doses tolerated by cynomolgus monkeys. Int J Cancer 81:148-155
23. Kreitman RJ, Wilson WH, White JD, Stetler-Stevenson M, Jaffe ES, Giardina S, Waldmann TA, Pastan I (2000) Phase I trial of recombinant immnuotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies. J Clin Oncol 18:1622-1636
24. Kreitman RJ, Wilson WH, Bergeron K, Raggio M, Stetler-Stevenson M, FitzGerald DJ, Pastan I (2001) Efficiency of the anti-CD22 recombinant immnuotoxin BL22 chemotherapy-resistant hairy-cell leukemia. N Engl J Med 345:241-247
25. Kreitman RJ, Hassan R, Fitzgerald DJ, Pastan I (2009) Phase I trial of continuous infusion anti-mesothelin recombinant immunotoxin SS1P. Clin Cancer Res 15:5274-5279
26. Kreitman RJ, Tallman MS, Robak T, Coutre S, Wilson WH, Stetler-Stevenson M, Fitzgerald DJ, Lechleider R, Pastan I (2012) Phase I trial of anti-CD22 recombinant immunotoxin Moxetumomab Pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia. J Clin Oncol. doi: 10.1200/JCO.2011.38.1756, epublish ahead of print
27. Kuan CT, Pastan I (1996) Improved antitumor activity of a recombinant anti-Lewis(y) immunotoxin not requiring proteolytic activation. Proc Natl Acad Sci U S A 93:974-978
28. 125I-labled anti-epidermal growth factor receptor-vIII single-chain Fv exhibits specific and high-level targeting of glioma xenografts. Clin Cancer Res 5:1539-1549
29. Kuan CT, Wikstrand CJ, Archer G, Beers R, Pastans T, Zalutsky M, Bigner DD (2000) Increased binding affinity enhances targeting of glioma zenografts by EGFRvIII-specific scFv. Int J Cancer 88:962-969
30. Lorimer IAJ, Wikstrand CJ, Batra SK, Bigner DO, Pastan I (1995) Immunotoxins that target an oncogenic mutant epidermal growth factor receptor expressed in human tumors. Clin Cancer Res 1:859-864
31. Lorimer IJ, Keppler-Hafkemeyer A, Beers RA, Pegram CN, Bigner DD, Pastan I (1996) Recombinant immunotoxins specific for a mutant epidermal growth factor receptor: targeting with a single chain antibody variable domain isolated by phage display. Proc Natl Acad Sci U S A 93:14815-14820
32. Mansfield E, Chiron MF, Amlot P, Pastan I, FitzGerald DJ (1997a) Recombinant RFB4 single-chain immunotoxin that is cytotoxic towards CD22-positive cells. Biochem Soc Trans 25:709-714
33. Mansfield E, Amlot P, Pastan I, FitzGerald DJ (1997b) Recombinant RFB4 immunotoxin exhibit potent cytotoxic activity for CD-22-bearing cells and tumors. Blood 90:2020-2026
34. Near RI, Ng SC, Mudgett-Hunter M, Hudson NW, Margolies MN, Seidman JG, Haber E, Jacobson MA (1990) Heavy and light chain contributions to antigen binding in an anti-digoxin chain recombinant antibody produced by transfection of cloned anti-digoxin antibody genes. Mol Immunol 27:901-909
35. Onda M, Beers R, Xiang L, Lee B, Weldon JE, Kreitman RJ, Pastan I (2011) Recombinant immunotoxin against B-cell malignancies with no immunogenicity in mice by removal of B-cell epitopes. Proc Natl Acad Sci U S A 108:5742-5747
36. Pai LH, Wittes R, Setser A, Willingham MC, Pastan I (1996) Treatment of advanced solid tumors with immnuotoxin LMB-1: an antibody linked to Pseudomonas exotoxin. Nat Med 2:350-353
37. Pastan I, Hassan R, FitzGerald DJ DJ, Kreitman RJ (2006) Immunotoxin therapy of cancer. Nat Rev Cancer 6:559-565
38. Pirker R, FitzGerald DJ, Hamilton TC, Ozols RF, Laird W, Frankel A, Willingham MC, Pastan I (1985) Characterization of immunotoxins active against ovarian cancer cells. J Clin Invest 76:1261-1267
39. Reisfeld RA, Gillies SD (1996) Recombinant antibody fusion proteins for cancer immunotherapy. Curr Top Microbiol Immunol 213:27-53
40. Reiter Y (2001) Recombinant immunotoxins is targeted cancer cell therapy. Adv Cancer Res 81:93-124
41. Reiter Y, Brinkmann U, Kreitman RJ, Jung SH, Lee B, Pastan I (1994) Stabilization of the Fv fragments in recombinant immunotoxins by disulfide bonds engineered into conserved framework regions. Biochemistry 33:5451-5459
42. Shankar S, Vaidyanathan G, Kuan CT, Bigner DD, Zalutsky MR (2006) Antiepidermal growth factor variant III scFv fragment: effect of radioiodination method on tumor targeting and normal tissue clearance. Nucl Med Biol 33:101-110
43. Wayne AS, Kreitman RJ, Findley HW, Lew G, Delbrook C, Steinberg SM, Stetler-Stevenson M, Fitzgerald DJ, Pastan I (2010) Anti-CD22 immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-positive hematologic malignancies of childhood: preclinical studies and phase I clinical trial. Clin Cancer Res 16:1894-1903
44. Wikstrand CJ, Hale LP, Batra SK, Hill MI, Humphrey PA, Kurpad SN, Mclendon RE, Moscatello D, Pegram CN, Reist CJ, Traweek ST, Wong AJ, Zalutsky MR, Bigner DD (1995) Monoclonal-antibodies against EGFRvIII are tumor-specific and react with breast and lung carcinomas and malignant gliomas. Cancer Res 55:3140-3148
45. Wikstrand CJ, Reist CJ, Archer GE, Zalutsky MR, Bigner DD (1998) The class III variant of the epidermal growth factor receptor (EGFRvIII): characterization and utilization as an immunotherapeutic target. J Neuro Virol 4:148-158
46. Wikstrand CJ, Cokgor I, Sampson JH, Bigner DD (1999) Monoclonal antibody of human glioma: current status and future approaches. Cancer Metastasis Rev 18:451-464
47. Yamazaki H, Ohba Y, Tamaoki N, Shibuya M (1990) A deletion mutation within the ligand binding domain is responsible for activation of epidermal growth factor receptor gene in human brain tumors. Jap J Cancer Res 81:773-779
48. Yokata T, Milenic DE, Withlow M, Schlom J (1992) Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms. Cancer Res 52:3402-3408
49. Zhang Y, Chertov O, Zhang J, Hassan R, Pastan I (2011) Cytotoxic activity of immunotoxin SS1P is modulated by TACE-dependent mesothelin shedding. Cancer Res 71:5915-5922